Kiora Pharma appoints Susan L. Drexler as Interim CFO effective Apr 21, 2022
KIORA PHARMACEUTICALS INC
Susan L. Drexler appointed Interim CFO, principal accounting officer and principal financial officer effective April 21, 2022.
Over 25 years of life science CFO experience; previously CFO of Harmony Biosciences (HRMY) and roles at Ocugen, Shire.
Services provided via Danforth Advisors consulting agreement at $450/hour; termination requires 30 days (with cause) or 60 days (without cause) notice.
No family relationship or reportable transactions between Drexler and any Kiora director or executive officer.
On April 21, 2022 (the “Effective Date”), the Board of Directors of Kiora Pharmaceuticals Inc. (the “Company”) appointed Susan L. Drexler as Interim Chief Financial Officer of the Company, effective as of the Effective Date.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Susan L. Drexler was appointed as Interim Chief Financial Officer at KIORA PHARMACEUTICALS INC.
Action
appointed
Role
Interim Chief Financial Officer
Exact text from the filing
On April 21, 2022 (the “Effective Date”), the Board of Directors of Kiora Pharmaceuticals Inc. (the “Company”) appointed Susan L. Drexler as Interim Chief Financial Officer of the Company, effective as of the Effective Date.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.